Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Case Report of Non–Small Cell Lung Cancer with STRN-ALK Translocation: A Nonresponder to Alectinib

21 Nov 2017

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related gene regulation
Share to Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
Share to Lung Cancer Treatments and Mutations

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 29169525
DOI: 10.1016/j.jtho.2017.08.009

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Case Report of Non–Small Cell Lung Cancer with STRN-ALK Translocation: A Nonresponder to AlectinibPMID 29169525Read ↗

ALK rearrangements: Biology, detection and opportunities of therapy in non-small cell lung cancerSemantic proximity Read ↗

STRN-ALK Fusion in Lung Adenocarcinoma with Brain Metastasis Responded Well to Ensartinib: A Case ReportSemantic proximity Read ↗

The Biology and Clinical Features of Non–small Cell Lung Cancers with EML4-ALK TranslocationSemantic proximity Read ↗

Mixed responses to first‐line alectinib in non‐small cell lung cancer patients with rare ALK gene fusions: A case series and literature reviewSemantic proximity Read ↗

Unique molecular features and clinical outcomes in young patients with non-small cell lung cancer harboring ALK fusion genesSemantic proximity Read ↗

ALK and ROS1 non-small-cell lung cancer: two molecular subgroups sensitive to targeted therapy.Semantic proximity Read ↗

Clinical consequences of resistance to ALK inhibitors in non-small cell lung cancer.Semantic proximity Read ↗

Safety of alectinib for the treatment of metastatic ALK-rearranged non-small cell lung cancer.Semantic proximity Read ↗

Therapeutic Advances of Rare ALK Fusions in Non-Small Cell Lung CancerSemantic proximity Read ↗

EML4-ALK: Update on ALK InhibitorsSemantic proximity Read ↗

EML4-ALK Fusion as a Resistance Mechanism to Osimertinib and Its Successful Management With Osimertinib and Alectinib: Case Report and Review of the LiteratureSemantic proximity Read ↗

Lung adenocarcinoma harboring concomitant EGFR mutation and EML4-ALK fusion that benefits from three kinds of tyrosine kinase inhibitors: a case report and literature review.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.